The FLOW trial (Perkovic et al., New England Journal of Medicine , 2024) specifically studied semaglutide in CKD patients and found no need for dose adjustment
The ipamorelin peptide has been extensively studied in preclinical research models for its selective activation of growth hormone release pathways
However, given the small sample sizes of these RCTs, the generalizability of the findings is limited
I don't know much about much, but I know a lot about lips, and I feel like Not Beauty is not beauty
Note: Responses have been edited for length/clarity.
Sass JO, Gemperle-Britschgi C, Tarailo-Graovac M, Patel N, Walter M, Jordanova A, Alfadhel M, Baric I, Coker M, Damli-Huber A, et al